Gastric Cancer

524

Pipeline Programs↗

242

Active Trials↗

132

Companies Involved↗

Gastric Cancer is a highly competitive landscape with 524 programs across 132 companies. The most active players are Base Therapeutics (Shanghai) Co., Ltd., Risen (Suzhou) Pharma Tech Co., Ltd., EMD Serono Research & Development Institute, Inc.. 26 therapies are approved with 129 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

97/100

Pipeline Velocity

70/100

Mech. Concentration

8/100

Completion Rate

82/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Base Therapeutics (Shanghai) Co., Ltd.

2 programs

Risen (Suzhou) Pharma Tech Co., Ltd.

2 programs

EMD Serono Research & Development Institute, Inc.

1 program

AnewPharma

1 program

Minneamrita Therapeutics LLC

1 program

Turning Point Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical26

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Gemcitabine

Johnson & Johnson

Glutamine

Sanofi

Capecitabine, Oxaliplatin

Peking Union Medical College Hospital

PD-1 Inhibitor

Johnson & Johnson

Phase 152

Veliparib

AbbVie

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Bleomycin

Bristol-Myers Squibb

Dalpiciclib

Risen (Suzhou) Pharma Tech Co., Ltd.

Mitoxantrone Hydrochloride

Pfizer

Phase 2291

Pyrotinib

Hengrui Therapeutics, Inc.

Pemetrexed Disodium

Gynecologic Oncology Group

Regorafenib

Bayer

Lapatinib

GSK

Antineoplaston A10

Burzynski Research Institute

Phase 3129

Zolbetuximab

Astellas

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Epirubicin Hydrochloride

Merck & Co.

Serplulimab

Shanghai Henlius Biotech

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved26

Thalidomide

Bristol-Myers Squibb

Crizotinib

Prism Pharmaceuticals

Oxaliplatin

Teva

Vandetanib

Genzyme, a Sanofi Company

Eflornithine

USWM, LLC (dba US WorldMeds)

Analysis

Modality Breakdown

86%

Small molecule

583 of 679 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 679 classified programs, each share of the total. Modality classified for 99% of 715 pipeline programs.

Analysis

Trial Status

886

clinical trials

Unknown status292 · 33%

Completed286 · 32%

Recruiting124 · 14%

Not yet recruiting72 · 8%

Terminated47 · 5%

Active, not recruiting44 · 5%

Other21 · 2%

Clinical Trials

Trial Activity

886 trials

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Recruiting·RRuijin Hospital·Phase 2·NCT06519591·40 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Recruiting·FFujian Cancer Hospital·Phase 2/3·NCT05699655·130 enrolled

An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II

Recruiting·RResearch Institute for Physical Chemical Problems of the Belarusian State University·Phase 2/3·NCT06232434·120 enrolled

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Recruiting·ECOG-ACRIN Cancer Research Group·Phase 2/3·NCT07001748·148 enrolled

PROGAIN Trial in Gastric Cancer Surgery

Recruiting·SSoonchunhyang University Hospital·Phase 3·NCT07488611·100 enrolled

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

Recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT06059495·59 enrolled

Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery

Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07119463·112 enrolled

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

Recruiting·UUkrainian Society of Clinical Oncology·Phase 3·NCT06755554·105 enrolled

PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07294664·36 enrolled

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06623396·18 enrolled

MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Recruiting·—·N/A·NCT02988921·300 enrolled

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 2·NCT06791083·40 enrolled

Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer

Recruiting·—·Phase 3·NCT04483076·524 enrolled

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Recruiting·SShanghai Minimally Invasive Surgery Center·Phase 2·NCT06036745·20 enrolled

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting·HHallym University Medical Center·Phase 3·NCT04787354·976 enrolled

Page 1 of 60

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)